All companies › PRCT

PRCT · PROCEPT BioRobotics Corp

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research signal for this company.

1
Open-market buys
0
Open-market sells
1
INSIDER SCANNER signals
2026-08-07
Last filing

Insider flow: Buying only — a count of disclosed transactions, not a rating or a recommendation.

INSIDER SCANNER signals for PRCT

Research signals this company has produced, with the reasoning recorded at the time.

B · MEDIUM conviction · SWING · 2026-08-07
21.75Entry reference
23.93Model target
30.0Max hold (days)
15.0%Model allocation
Wood Larry L · Pres, CEO

President/CEO Larry Wood bought ~$498K solo, delta_own 8%, single insider (no cluster) — real C-suite money into a name near its 52w low after a ~49% drawdown. Fundamentals support the thesis with 19% revenue growth and 64% gross margin, and the healthcare sector is beating SPY by ~13%. But RSI 70 is already extended into resistance at ma50, and a securities class-action lawsuit over an alleged handpiece discount program that inflated recurring revenue is a serious overhang — small position only.

Watch: Class-action lawsuit filed Aug 2026 alleging inflated recurring revenue; multiple analyst downgrades (Truist, William Blair, Leerink); unprofitable with negative FCF; RSI overbought at entry; no cluster.

SEC Form 4 filings

Every open-market transaction disclosed for PRCT in the synced window. Values are the insider's own, as filed.

DateInsiderTitleTypeSharesPriceValue
2026-08-07 Wood Larry L President, CEO Open-market buy 23,900 20.85 $498,315

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.